-
Product Insights
NewNet Present Value Model: iTeos Therapeutics Inc’s Belrestotug
Empower your strategies with our Net Present Value Model: iTeos Therapeutics Inc's Belrestotug report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: iTeos Therapeutics Inc’s Inupadenant hydrochloride
Empower your strategies with our Net Present Value Model: iTeos Therapeutics Inc's Inupadenant hydrochloride report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of iTeos Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of iTeos Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EOS-984 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EOS-984 in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EOS-984 in Solid Tumor Drug Details: EOS-984 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Melanoma Drug Details: EOS-850 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inupadenant Hydrochloride in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inupadenant Hydrochloride in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inupadenant Hydrochloride in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Belrestotug in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Belrestotug in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Belrestotug in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TIDAL-01 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TIDAL-01 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TIDAL-01 in Triple-Negative Breast Cancer (TNBC) Drug Details: TIDAL-01...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Conestat Alfa in Delayed Graft Function (DGF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Conestat Alfa in Delayed Graft Function (DGF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Conestat Alfa in Delayed Graft Function (DGF) Drug Details:...